Eli Lilly Raises 2026 Revenue Outlook to $91B-$92B on 39% Q3 Growth; LLY Jumps 8%

Eli Lilly and Co. (LLY) raised its full-year 2026 revenue guidance to $91 billion-$92 billion from $85 billion-$87 billion, lifting the midpoint by $5.5 billion, after third-quarter revenue rose 39% to $24.397 billion on strong Mounjaro and Zepbound demand. Shares traded at $1,392.55, up 8.06%. For the quarter ended September 30, 2026, net income was $6.451 billion, or $7.22 per share, versus $5.583 billion, or $6.21 per share, a year earlier. Adjusted EPS was $7.48, including $4.57 in acquired IPR&D charges tied to the AtaiBeckley and Curevo acquisitions. Lilly lowered 2026 adjusted EPS guidance to $35.00-$36.00 from $35.50-$36.50, citing the acquisition charges, while raising its performance margin outlook to 52.0%-52.5%. Mounjaro revenue climbed 65% to $10.72 billion and U.S. Zepbound revenue rose 49% to $5.35 billion. The company cited FDA approvals for Mounjaro in cardiovascular risk reduction, Onswik, Inluriyo and an expanded Jaypirca indication.